The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients

Eur Heart J. 2023 Oct 1;44(37):3492-3494. doi: 10.1093/eurheartj/ehad429.

Authors

J Hans DeVries^{1

2}, Alar Irs³, Hans L Hillege⁴

Affiliations

¹ Seconded National Expert, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, the Netherlands.
² Department of Internal Medicine, Amsterdam UMC, Locatie AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
³ CHMP member, State Agency of Medicines, Tartu, Estonia.
⁴ CHMP member, Medicines Evaluation Board, Utrecht, the Netherlands.

No abstract available

MeSH terms

Adult
Benzylamines
Cardiomyopathy, Hypertrophic*
Humans
Uracil

Substances

MYK-461
Benzylamines
Uracil